| Heading: |
Drugs: Prices |
| Question ID: |
1805783 |
| UIN: |
54543 |
| House: |
Commons |
| Date tabled: |
2025-05-22 |
| Asking Member ID: |
5312 |
| Asking Member display name: |
Sadik Al-Hassan
|
| Asking Member handle: |
|
| Asking Member Twitter reference: |
Sadik Al-Hassan
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of NHS England’s criterion for eligibility for indication-specific pricing to demonstrate revenue loss on the UK’s international competitiveness |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-06-06 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
The Government is taking decisive steps to secure the future of life sciences research in the United Kingdom and to ensure we remain internationally competitive. The upcoming Life Sciences Sector Plan sets out a bold vision to strengthen our world-class r... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |